论文部分内容阅读
目的:分析依那普利联合丹参酮在肺心病急性加重期患者治疗中的疗效及影响,评价其安全性。方法:将新乡医学院第一附属医院收治的114例肺心病急性加重期的患者,随机分成观察组和对照组,每组各57例。对照组在临床常规治疗的基础上应用依那普利治疗,观察组在对照组治疗的基础上联合应用丹参酮,对治疗后两组临床疗效进行评定,同时对治疗前后患者血气及血液流变学等指标监测,并进行分析比较。结果:观察组与对照组的有效率分别为94.7%,80.7%,观察组显著高于对照组(P<0.05);两组患者治疗前后在血气、血液流变学及心功能等指标均有显著差异(P<0.05),同时观察组患者治疗前后的指标差值明显优于对照组(P<0.05);两组不良反应情况差异无明显不同。结论:依那普利联合丹参酮治疗肺心病急性加重期的患者疗效显著,且安全有效,不良反应可耐受,值得临床应用推广。
OBJECTIVE: To analyze the efficacy and impact of enalapril combined with tanshinone in the treatment of patients with acute exacerbation of pulmonary heart disease, and evaluate its safety. Methods: One hundred and fourteen patients with acute exacerbation of pulmonary heart disease admitted to the First Affiliated Hospital of Xinxiang Medical College were randomly divided into observation group and control group, 57 cases in each group. The control group was treated with enalapril on the basis of routine clinical treatment. The observation group was treated with tanshinone on the basis of the control group, and the clinical efficacy of both groups was evaluated. The blood gas and hemorheology And other indicators of monitoring, and analysis and comparison. Results: The effective rates of the observation group and the control group were 94.7% and 80.7%, respectively, and the observation group was significantly higher than that of the control group (P <0.05). Before and after treatment, blood gas, hemorheology and cardiac function (P <0.05). Meanwhile, the differences between the observation group and the control group before and after treatment were significantly better than those of the control group (P <0.05). There was no significant difference in adverse reactions between the two groups. Conclusion: Enalapril combined with tanshinone in the treatment of acute exacerbation of pulmonary heart disease patients with significant effect, and safe and effective, adverse reactions can tolerate, it is worth promoting the clinical application.